Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-05-11
2003-11-04
Reamer, James H. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S428000
Reexamination Certificate
active
06642262
ABSTRACT:
This application is a continuation of International application No. PCT/FR99/02,753, filed Nov. 09, 1999; which claims the benefit of priority of French Patent Application No. 98/14,250, filed Nov. 13, 1998.
The present invention relates to the combination of &agr;-tocopherol and of riluzole or of a pharmaceutically acceptable salt of this compound and the use of this combination for the treatment of amyotrophic lateral sclerosis (ALS).
Amyotrophic lateral sclerosis, also known by the name of CHARCOT's disease and LOU GEHRIG's disease, was described for the first time by CHARCOT in 1865. ALS is a fatal disease resulting from degeneration of the motoneurons. The disease is accompanied by progressive paralysis, leading to the loss of motor and respiratory functions and then to death within a period of two to eight years after the appearance of the first symptoms.
To date, only riluzole (2-amino-6-trifluoromethoxybenzothiazole) is marketed under the name RILUTEK® for the treatment of amyotrophic lateral sclerosis. Riluzole makes it possible mainly to slow down the progression of the disease.
It has now been found that the combination of riluzole or one of its pharmaceutically acceptable salts and of &agr;-tocopherol (vitamin E) makes it possible to slow down the disease more substantially than riluzole alone and also to reduce fatigue in patients and the plasma concentration of malondialdehyde.
The study was carried out in 289 patients in total aged over 18 years, who have been suffering from ALS for less than 5 years and in whom the vital capacity/theoretical normal vital capacity ratio is greater than or equal to 60% (the vital capacity is a routine conventional measurement of the respiratory function also called lung function test).
The patients are divided into 2 groups:
group 1: 145 patients treated with 100 mg/day of riluzole by the oral route and 1000 mg/day of &agr;-tocopherol by the oral route,
group 2: 144 patients treated with 100 mg/day of riluzole by the oral route and placebo.
Some patients in the 2 groups no longer meeting, in a second evaluation, the inclusion criteria or who had not followed the treatment correctly, were not taken into account for the determination of the results.
The patients are monitored for a year. The results are measured on functional scales (Munsat's functional states (RIVIERE et al., Arch. Neurol., 55, 526 (1998)), a visual analog scale (VAS) for fatigability (LACOBLEZ et al., The Lancet, 347, 1425 (1996); BENSIMON et al., New England Journal of Medicine, 330, 585 (1994)) and plasma concentration of malondialdehyde, a biochemical marker for oxidative stress (FAVIER, Analysis of free radicals in biological systems, Birk Hauser, Basel/Switzerland, 1995 p. 100-117).
REFERENCES:
patent: 5780489 (1998-07-01), Brooks
patent: 5849290 (1998-12-01), Brown et al.
patent: 5964224 (1999-10-01), Kaji
Ross, M.A.: “Acquired motor neuron disorders”Neurologic Clinics(Neurol. Clin.), 1997, 15/3 pp. (481-500).
Gurney, ME., et al: “Pathogenic mechanisms in familial amyotrophic lateral sclerosis due to mutation of Cu, Zn superoxide dismutase”Pathol Biol(Paris), Jan. 1996, 44(1) pp. 51-56.
Miller, R.G.: “New approaches to therapy of amyotrophic lateral sclerosis”Western Journal of Medicine(West.J.Med), 168/4 pp. 262-263 (1998).
Riviere, M., et al:Arch Neurol., 55, pp. 526-528 (1998).
Lacomblez, L., et al:The Lancet, 347, pp. 1425-1431 (1996).
Bensimon, A.E.:The New England Journal of Medicine, 330, pp. 585-591 (1994).
Favier et al:Analysis of Free Radicals in Biological Systems, Birk Hauser, Basel/Switzerland (1995) pp. 100-117.
Aventia Pharma S.A.
Gupta Balaram
Reamer James H.
LandOfFree
Riluzole and alpha-tocopherol combination does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Riluzole and alpha-tocopherol combination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Riluzole and alpha-tocopherol combination will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3131007